This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

I. N. Ferrier, MRCP, MRCPsych, MD
Medical Research Council Neuroendocrinology Unit Newcastle Upon Tyne NE4 6BE England

Eve C. Johnstone, FRCPsych, MD; T. J. Crow, FRCP, FRCPsych, PhD
Clinical Research Centre Harrow, Middlesex HAI 3UJ England

Arch Gen Psychiatry. 1987;44(1):93.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Several studies have demonstrated a wide scatter of growth hormone response to the dopamine agonist apomorphine in patients with a diagnosis of schizophrenia.^1-4 Recently, Whalley et al⁵ reported that psychotic patients with Schneider's first-rank symptoms had a significantly greater growth hormone response to apomorphine than did those patients without such symptoms. However, our own study⁵ suggests that within the schizophrenic population the presence of first-rank symptoms is unlikely to be the factor that accounts for variation in this response.

We studied 15 male patients not taking medication who had acute schizophrenia. The symptoms were less than one month old when the patients were tested. All of the patients had at least one nuclear symptom as assessed by the Present State Examination⁶; in practice (as discussed by Whalley et al⁵) this is equivalent to the presence of Schneider's first-rank symptoms. The growth hormone . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?